Physician profile
Mark E Ohm
NPI 1245236058
$2,697.91
in general payments reported to CMS, 2019-2025
27 companies · $559 in 2025
The $559 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $140 · 2021: $411 · 2022: $505 · 2023: $449 · 2024: $502 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,510.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $296.75 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $282.99 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $248.83 | 2021-2025 | |
| Sage Therapeutics, LLC | $232.02 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $206.61 | 2019-2022 | |
| Hologic Sales and Service, LLC | $172.09 | 2019-2025 | Coolseal Generator, Aptima, Thinprep 2000 Processor |
| Daiichi Sankyo INC. | $144.82 | 2020-2025 | Injectafer |
| Aspira Women'S Health INC | $143.85 | 2021-2022 | |
| Exeltis, USA INC. | $119.74 | 2020-2025 | Slynd |
| Astellas Pharma US INC | $112.48 | 2023-2024 | Veozah |
| Organon LLC | $109.49 | 2022-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $74.11 | 2019-2023 | |
| Currax Pharmaceuticals LLC | $68.55 | 2020-2024 | Contrave |
| Pfizer INC. | $64.61 | 2024-2025 | |
| Millicent US INC | $64.36 | 2024-2025 | Femlyv, Femring, Intrarosa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $57.50 | 2022 | |
| Exact Sciences Corporation | $56.73 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $44.93 | 2025 | Zepbound |
| Coopersurgical, INC. | $39.44 | 2020-2024 | Paragard T 380a |
| Meditrina | $35.41 | 2023-2024 | |
| Novo Nordisk INC | $26.00 | 2025 | Wegovy |
| Channel Medsystems, INC. | $23.82 | 2025 | |
| Evofem Biosciences, INC. | $19.13 | 2022 | |
| Mission Pharmacal Company | $15.31 | 2020 | |
| Merck Sharp & Dohme LLC | $13.85 | 2020 | |
| Avion Pharmaceuticals | $12.72 | 2019 | |
| Duchesnay USA Incorporated | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ohm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.